<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9962240</article-id><article-id pub-id-type="pmcid-ver">PMC9962240.1</article-id><article-id pub-id-type="pmcaid">9962240</article-id><article-id pub-id-type="pmcaiid">9962240</article-id><article-id pub-id-type="pmid">36851368</article-id><article-id pub-id-type="doi">10.3390/vaccines11020491</article-id><article-id pub-id-type="publisher-id">vaccines-11-00491</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Respiratory Syncytial Virus Infection: Treatments and Clinical Management</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Malik</surname><given-names initials="S">Shiza</given-names></name><xref rid="af1-vaccines-11-00491" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="T">Tahir</given-names></name><xref rid="af2-vaccines-11-00491" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6488-1722</contrib-id><name name-style="western"><surname>Muhammad</surname><given-names initials="K">Khalid</given-names></name><xref rid="af3-vaccines-11-00491" ref-type="aff">3</xref><xref rid="c1-vaccines-11-00491" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5789-4215</contrib-id><name name-style="western"><surname>Waheed</surname><given-names initials="Y">Yasir</given-names></name><xref rid="af4-vaccines-11-00491" ref-type="aff">4</xref><xref rid="af5-vaccines-11-00491" ref-type="aff">5</xref><xref rid="c1-vaccines-11-00491" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Cosby</surname><given-names initials="SL">S. Louise</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>De la Torre</surname><given-names initials="JC">Juan C.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-11-00491"><label>1</label>Bridging Health Foundation, Rawalpindi 46000, Pakistan</aff><aff id="af2-vaccines-11-00491"><label>2</label>Industrial Biotechnology, Atta ur Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad 44000, Pakistan</aff><aff id="af3-vaccines-11-00491"><label>3</label>Department of Biology, College of Science, UAE University, Al Ain 15551, United Arab Emirates</aff><aff id="af4-vaccines-11-00491"><label>4</label>Office of Research, Innovation, and Commercialization (ORIC), Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad 44000, Pakistan</aff><aff id="af5-vaccines-11-00491"><label>5</label>Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Byblos 1401, Lebanon</aff><author-notes><corresp id="c1-vaccines-11-00491"><label>*</label>Correspondence: <email>k.muhammad@uaeu.ac.ae</email> (K.M.); <email>yasir_waheed_199@hotmail.com</email> (Y.W.)</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>2</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2023</year></pub-date><volume>11</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">428735</issue-id><elocation-id>491</elocation-id><history><date date-type="received"><day>07</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>29</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>17</day><month>2</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>02</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>02</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-04-26 21:25:14.187"><day>26</day><month>04</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-11-00491.pdf"/><abstract><p>Respiratory syncytial virus (RSV) is a major healthcare concern, especially for immune-compromised individuals and infants below 5 years of age. Worldwide, it is known to be associated with incidences of morbidity and mortality in infants. Despite the seriousness of the issue and continuous rigorous scientific efforts, no approved vaccine or available drug is fully effective against RSV. The purpose of this review article is to provide insights into the past and ongoing efforts for securing effective vaccines and therapeutics against RSV. The readers will be able to confer the mechanism of existing therapies and the loopholes that need to be overcome for future therapeutic development against RSV. A methodological approach was applied to collect the latest data and updated results regarding therapeutics and vaccine development against RSV. We outline the latest throughput vaccination technologies and prophylactic development efforts linked with RSV. A range of vaccination approaches with the already available vaccine (with limited use) and those undergoing trials are included. Moreover, important drug regimens used alone or in conjugation with adjuvants or vaccines are also briefly discussed. After reading this article, the audience will be able to understand the current standing of clinical management in the form of the vaccine, prophylactic, and therapeutic candidates against RSV. An understanding of the biological behavior acting as a reason behind the lack of effective therapeutics against RSV will also be developed. The literature indicates a need to overcome the limitations attached to RSV clinical management, drugs, and vaccine development that could be explained by dealing with the challenges of current study designs with continuous improvement and further work and approval on novel therapeutic applications.</p></abstract><kwd-group><kwd>respiratory syncytial virus</kwd><kwd>RSV infection</kwd><kwd>therapeutics</kwd><kwd>antiviral agents</kwd><kwd>vaccines</kwd><kwd>therapies</kwd><kwd>treatment</kwd><kwd>novel therapeutic</kwd><kwd>clinical management</kwd></kwd-group><funding-group><award-group><funding-source>United Arab Emirates University</funding-source><award-id>#G3458</award-id></award-group><award-group><funding-source>SURE plus</funding-source><award-id>#3908</award-id></award-group><award-group><funding-source>SDG research program</funding-source><award-id>#4065</award-id></award-group><funding-statement>K.M.&#8217;s work is supported by the United Arab Emirates University UPAR-Grant#G3458, SURE plus Grant#3908 and SDG research program grant#4065.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-11-00491"><title>1. Introduction</title><p>Historically, respiratory syncytial virus (RSV) was discovered in 1956 as the causative agent of lower-respiratory-tract infections (LRTI) in children worldwide [<xref rid="B1-vaccines-11-00491" ref-type="bibr">1</xref>]. It also causes infection in elderly and immune-compromised individuals. This is unlike in pediatric patients, for which understanding is well developed [<xref rid="B2-vaccines-11-00491" ref-type="bibr">2</xref>]. There is a general lack of understanding of RSV infection and transmission routes in elderly patients. It should be noted that RSV majorly causes infection in babies in forms of inflammation (pneumonia) or bronchiolitis (inflammation of the lungs and airways). The infection develops in the form of a runny nose, low fever, sore throat, dry cough, sneezing, headache, and breathing difficulty. Hospitalization and death cases have also been recorded worldwide, especially in infants. Thus, there is urgent need to call for immediate therapeutic development against RSV [<xref rid="B2-vaccines-11-00491" ref-type="bibr">2</xref>]. However, the vulnerable nature of an infant&#8217;s respiratory and immune system makes it difficult to develop effective vaccine candidates due to limited testability in children. The past vaccination trials of mid 20th century and the resultant hospitalization cases have also restricted the clinical research trials [<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>]. This aspect is further discussed later in this article.</p><p>Biologically, RSV belongs to the family Paramyxoviridae of viruses, characterized by a single-stranded RNA genome with a length of approximately 15 kB [<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-11-00491" ref-type="bibr">4</xref>]. This genome accounts for nearly 10 genes and 11 protein entities that involve surface glycoproteins and those involved in the fusion (F) and attachment (G) of the virus, among others [<xref rid="B5-vaccines-11-00491" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-11-00491" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-11-00491" ref-type="bibr">7</xref>]. These proteins also serve the purpose of antigenic targets for therapeutic and vaccine development. The relative antigenic differences among these proteins, especially glycoproteins, have resulted in the deviation of RSV into two subgroups (A and B) [<xref rid="B8-vaccines-11-00491" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-11-00491" ref-type="bibr">10</xref>]. In terms of physical characteristics, the RSV exists in spherical or long filamentous forms [<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>]. According to the reports of the WHO, RSV is responsible for a yearly ~39 million infection cases worldwide. Some of these infections reportedly lead to hospitalization (~3.6 million) and severe morbidity cases that lead to ~101,400 deaths per year [<xref rid="B12-vaccines-11-00491" ref-type="bibr">12</xref>]. This case is even more severe for developing countries with compromised healthcare and economic conditions. In these countries, the communities are considered as vulnerable to RSV as they are to influenza virus incidences, which is also quite common there [<xref rid="B12-vaccines-11-00491" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00491" ref-type="bibr">14</xref>].</p><p>Immunologically, the main features that make infants and children vulnerable to RSV infection may include an overall immunocompromised system that arises due to conditions such as premature birth conditions, age (&#8804;6 months&#8211;1 year), bronchopulmonary dysplasia, neuromuscular disorders, and compromised congenital heart and lung conditions at birth [<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>,<xref rid="B15-vaccines-11-00491" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-11-00491" ref-type="bibr">16</xref>]. Moreover, the risk factors also involve the male gender, the incidence of trisomy 21, and cystic fibrosis upon birth [<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>,<xref rid="B12-vaccines-11-00491" ref-type="bibr">12</xref>,<xref rid="B17-vaccines-11-00491" ref-type="bibr">17</xref>]. Clinically, RSV infection exhibits the features of sore throat, malaise, and coryza, in mild incidences [<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>]. However, in the case of the increased infectious form of LRTI, the clinical outcomes include low-grade fever, wheezing, dyspnea, cyanosis, and subcostal recession with consolidation. It causes 20% of pneumonia cases in infants [<xref rid="B19-vaccines-11-00491" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>].</p><p>The current treatment options are in the form of supportive and preventive options that are used for RSV-associated infant health management worldwide [<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>]. To date, no effective or approved therapeutics and vaccines are available to cure this virus disease [<xref rid="B12-vaccines-11-00491" ref-type="bibr">12</xref>]. Only short-time clinical benefits are achieved with the use of the available drugs and antivirals or with the hormonal treatment option (nebulized adrenalin), with little or no effect from chemotherapy based on hypertonic saline, a bronchodilator, glucocorticoid, etc. [<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>,<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>,<xref rid="B14-vaccines-11-00491" ref-type="bibr">14</xref>,<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00491" ref-type="bibr">23</xref>]. Several efforts are being put forth in the field of vaccinology and pharmaceutical for RSV clinical management. The preclinical and early clinical outcomes of these studies present hope that the future might hold the approval chances of an effective therapy option against RSV [<xref rid="B24-vaccines-11-00491" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-11-00491" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-11-00491" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>].</p><p>There exists massive information on RSV virology related to its replication, transmission, and pathogenesis, which enables therapeutic design against RSV infection. However, there still exists a gap in standardized global surveillance, diagnosis, and data management regarding RSV [<xref rid="B6-vaccines-11-00491" ref-type="bibr">6</xref>,<xref rid="B28-vaccines-11-00491" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>]. Moreover, there is a general inefficiency in prophylaxis and antiviral and vaccination strategies against RSV. This review revises our understanding of the general pathophysiological features of RSV infection and the experimental default lines that exist for therapeutic development against it [<xref rid="B30-vaccines-11-00491" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00491" ref-type="bibr">31</xref>]. Moreover, we mainly discuss different vaccination and therapeutic developments in the domain of RSV clinical management and the understanding of the lack of market approval for these tested drugs [<xref rid="B32-vaccines-11-00491" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-11-00491" ref-type="bibr">33</xref>,<xref rid="B34-vaccines-11-00491" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-11-00491" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-11-00491" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-11-00491" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-11-00491" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-11-00491" ref-type="bibr">39</xref>]. After reading this article, the audience will be able to understand the gaps in the literature and clinical developments that need to be undertaken via integrated and collaborative clinical research efforts so that RSV and associated infections can be well managed in the next couple of years.</p></sec><sec id="sec2-vaccines-11-00491"><title>2. Main Body</title><sec id="sec2dot1-vaccines-11-00491"><title>2.1. The Ever-Evolving and Mutational Nature of RSV</title><p>RSV types A and B are the causative agents of infectious human respiratory syncytial virus infection. The internal structural proteins of RSV consist of matrix protein (M) and nucleoprotein (N), which contribute to the functions of the polymerase complex consisting of phosphoprotein (P) and polymerase (L) [<xref rid="B40-vaccines-11-00491" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-11-00491" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-11-00491" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-11-00491" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-11-00491" ref-type="bibr">44</xref>]. Moreover, nonstructural proteins such as surface glycoproteins (G), small hydrophobic protein (SH), fusion protein (F), and the regulatory M2 proteins function to regulate the innate immune responses by acting as antigenic particles within the host body [<xref rid="B45-vaccines-11-00491" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-11-00491" ref-type="bibr">46</xref>]. They also function in the transcription and replication of virus particles. The overall RNA-dependent replication cycle is often faced with an error in the replication and proofreading mechanism [<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B47-vaccines-11-00491" ref-type="bibr">47</xref>].</p><p>Certain mutations are exhibited in the form of single-nucleotide polymorphisms (SNPs) and other point mutations that cause changes in virus virulence and, hence, the subsequent immune responses in the host [<xref rid="B48-vaccines-11-00491" ref-type="bibr">48</xref>]. Moreover, the changes also affect the therapeutic efficiency of antiviral agents that are ineffective against the specific viral genetic makeup [<xref rid="B32-vaccines-11-00491" ref-type="bibr">32</xref>]. These characteristics make it pertinent for the scientific community to offer a more integrated approach to designing a combination therapy involving the co-application of certain vaccines, drugs, and adjuvants with a prime boosting effect so that a universal therapy can be devised for the clinical management of future RSV infections [<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>,<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00491" ref-type="bibr">14</xref>].</p></sec><sec id="sec2dot2-vaccines-11-00491"><title>2.2. Updates on Vaccine Development against RSV</title><p>As of now, no specific RSV vaccines are licensed or approved for use at the worldwide level [<xref rid="B12-vaccines-11-00491" ref-type="bibr">12</xref>]. However, it is important to formulate a proper vaccine against RSV infections since the target group involves immune-compromised individuals that have higher chances of infection development; these may involve infants and children, the elderly, and pregnant women [<xref rid="B17-vaccines-11-00491" ref-type="bibr">17</xref>]. If the infected cases remain untreated, they are likely to increase mortality and hospitalization counts, thus creating a great burden on the healthcare system worldwide [<xref rid="B49-vaccines-11-00491" ref-type="bibr">49</xref>]. The failed experiments on inactivated and subunit vaccine formulations such as the formalin-inactivated alum-adjuvanted RSV vaccine (FI-RSV) have caused a stoppage or delay of further vaccination trials in infants owing to the clinical outcomes that resulted upon their application in children [<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>]. Scientists are, thus, sorting out ways to create better immune regulatory substances and therapeutic options that can manage the illness symptoms without causing any further increase in symptoms [<xref rid="B19-vaccines-11-00491" ref-type="bibr">19</xref>].</p><p>An ideal vaccine candidate should be able to induce immune responses rapidly and should be administered within the first month of birth to avoid infection that develops in the period ranging from the sixth week to the sixth month [<xref rid="B19-vaccines-11-00491" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>]. However, the major cause of delay in vaccine development and its clinical implication is the immunocompromised nature of infants and the presence of antibodies acquired from the mother, which delays and reduces the vaccine responses [<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>,<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>]. Since active vaccination is hurdled due to the passive immunization from the mother, the replicating and vector-based vaccines are the preferred choices for testing in infants rather than non-replication vaccines [<xref rid="B51-vaccines-11-00491" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-11-00491" ref-type="bibr">52</xref>]. In addition to these hurdles, several pieces of evidence validate the inferences about the development of effective vaccines against RSV. One of these implications is the chances of development of severe infection even with the chance of RSV infection development throughout life [<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B53-vaccines-11-00491" ref-type="bibr">53</xref>,<xref rid="B54-vaccines-11-00491" ref-type="bibr">54</xref>]. Secondly, the monoclonal antibody derived from palivizumab is effective against increased mortality and morbidity cases. Yet another implication comes from the correlation between the maternal antibody-based neutralization effect that offers immune responses to a certain degree and helps protect against hospitalization [<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B54-vaccines-11-00491" ref-type="bibr">54</xref>].</p><p>More specifically, the F and G proteins of RSV induce the induction of neutralizing antibody-based protective effects [<xref rid="B55-vaccines-11-00491" ref-type="bibr">55</xref>]. Thus, they often choose to design vaccines for cross-protective RSV strain responses. The F protein is comparatively even better at immune induction than the G protein and is more conserved among varying RSV strains compared to the G protein, which is conserved only at a few central protein sequences [<xref rid="B56-vaccines-11-00491" ref-type="bibr">56</xref>]. These passive and active antibody-mediated immune responses offer a preventive capacity against RSV disease. These vaccines are designed to avoid problems associated with preexisting immunity in infants from mothers and excessive immune evasion or elevation that could be problematic for immunocompromised vulnerable patients [<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>].</p><p>Several vaccination strategies have been evaluated recently such as live-attenuated, recombinant vector-based, peptide-based, and subunit vaccines, which are briefly discussed in the next section; examples of a few candidates under trial are presented in <xref rid="vaccines-11-00491-t001" ref-type="table">Table 1</xref>. Despite the increase in ongoing RSV vaccination trials, the investigation is mostly limited to phases 1 and 2a of clinical experimentation because several challenges remain [<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>,<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>,<xref rid="B57-vaccines-11-00491" ref-type="bibr">57</xref>]. A few causes are ethical concerns, the immunocompromised nature of patients, inefficient surveillance rates, and lack of research funding in the prevalent healthcare systems [<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>,<xref rid="B58-vaccines-11-00491" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-11-00491" ref-type="bibr">59</xref>].</p><p>Moreover, the useful profiles of RSV vaccines have also demonstrated limited clinical effectiveness in humans. Nonetheless, even though the vaccine candidates designed under various methods have exhibited good immunogenic profile in animal models, their impact in humans has largely remained ineffective, incompetent, and inclusive [<xref rid="B40-vaccines-11-00491" ref-type="bibr">40</xref>,<xref rid="B60-vaccines-11-00491" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-11-00491" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-11-00491" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-11-00491" ref-type="bibr">63</xref>]. Therefore, more effective vaccination trials are needed that may originate from different vaccination approaches coupled with widescale clinical experimentation on both animal and human subjects for improved vaccination protocols and their widescale applicability and approval. Some major vaccination approaches in the research lane for RSV management are briefly discussed next.
<table-wrap position="float" id="vaccines-11-00491-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-11-00491-t001_Table 1</object-id><label>Table 1</label><caption><p>Vaccines against RSV under clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sr. No. </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Candidates under Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Live-attenuated vaccines against RSV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine candidates based on(M2-2 gene deletion) (M2-2 regulates RNA replication)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>LID &#916;M2-2 vaccine</p></list-item><list-item><p>LID &#916;M2-2 1030s</p></list-item><list-item><p>LID cp &#916;M2-2</p></list-item><list-item><p>MEDI &#916;M2-2</p></list-item><list-item><p>MEDI-559</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine candidates based on SH gene deletion( SH gene regulates cell apoptosis and role in viral fusion )</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>The rA2cp248/404/1030&#916;SH vaccine</p></list-item><list-item><p>The MEDI&#8211;599 vaccine</p></list-item><list-item><p>OE4 (RSV-A2-dNS1-dNS2-</p></list-item><list-item><p>&#916;SH-dGm-Gsnull-line19F)</p></list-item><list-item><p>DB1 (RSV-A2-dNS-&#916;SH-BAF),</p></list-item><list-item><p>RSV cps2 vaccine</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-vaccines-11-00491" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-11-00491" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-11-00491" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-11-00491" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-11-00491" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-11-00491" ref-type="bibr">30</xref>,<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccine candidates based on NS2 gene deletion(NS2 gene regulates epithelial cell shedding and host IFN based immune responses)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>&#916;NS2/&#916;1313/1314L or MEDI-559</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-11-00491" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccines based on genes from RSV related viruses</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MEDI&#8211;534 vaccine (parainfluenza virus type 3 (PIV3) genome engineered to express RSV F protein)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-11-00491" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other vaccine candidates</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p><italic toggle="yes">cpts</italic>-248/404 vaccine</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vector-based vaccines</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus vector-based vaccine trials </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>GSK3003891A</p></list-item><list-item><p>VXA-RSV-f</p></list-item><list-item><p>Ad26.RSV.FA2</p></list-item><list-item><p>Ad35.RSV.FA2</p></list-item><list-item><p>RSV 001</p></list-item><list-item><p>ChAd155-RSV (GSK3389245A)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B3-vaccines-11-00491" ref-type="bibr">3</xref>,<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-11-00491" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">B.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIV3 vector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MEDI&#8211;534</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-vaccines-11-00491" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>,<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B28-vaccines-11-00491" ref-type="bibr">28</xref>],</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adenovirus vector and an MVA vector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MVA-RSV</p></list-item><list-item><p>MVA-BN</p></list-item><list-item><p>PanAd3-RSV and</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B17-vaccines-11-00491" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>,<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>,<xref rid="B57-vaccines-11-00491" ref-type="bibr">57</xref>],</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RSV vaccine designed on Simian adenovirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>PanAd3-RSV) (prime boost strategy)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00491" ref-type="bibr">14</xref>],</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant live-attenuated RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>RSV LID &#916;M2-2</p></list-item><list-item><p>RSV cps2, Lot RSV#005A</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Protein and nanoparticle-based vaccines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>RSV sF antigen + synthetic glucopyranosyl lipid A adjuvant</p></list-item><list-item><p>F-protein nanoparticle + aluminum hydroxide adjuvant</p></list-item><list-item><p>MEDI-7510 (Post-fusion F glycoprotein + glucopyranosyl lipid A adjuvant)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B69-vaccines-11-00491" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-11-00491" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-11-00491" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-11-00491" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-11-00491" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-11-00491" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-11-00491" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-11-00491" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-11-00491" ref-type="bibr">78</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccines against RSV</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MEDI 7510 (RSV sF antigen + synthetic TLR-4 agonist /with or without synthetic glucopyranosyl lipid A adjuvant)</p></list-item><list-item><p>RSV F subunit vaccine</p></list-item><list-item><p>GSK3003891A (Prefusion F subunit vaccine)</p></list-item><list-item><p>Novavax&#8217;s RSV (F-protein nanoparticle vaccine (with and without an aluminum hydroxide adjuvant)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-vaccines-11-00491" ref-type="bibr">7</xref>,<xref rid="B53-vaccines-11-00491" ref-type="bibr">53</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>,<xref rid="B73-vaccines-11-00491" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-11-00491" ref-type="bibr">74</xref>]</td></tr></tbody></table></table-wrap>
</p><sec id="sec2dot2dot1-vaccines-11-00491"><title>2.2.1. Live-Attenuated Vaccines against RSV</title><p>The failure of inactivated vaccine formulations in the 1960s led to experiments in live-attenuated vaccine designs. These vaccines are prepared by rendering the virus ineffective by treating it with chemicals, radiation, or extreme temperatures [<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>]. Moreover, the virus may be subjected to genetic deletions for the maintenance of only a limited tendency of the virus genome for replication and antigenic representation in hosts [<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>]. A well-known procedure involves the deletion of a large segment of the M2-2 gene that plays a vital role in RNA replication. On one hand, it decreases the viral replication; in contrast, it causes increased expression of F and G proteins that act as antigenic representations and make the virus adequately attenuated for immune responses in the form of the production of neutralizing antibodies [<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-11-00491" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>]. The risk of de-attenuation is kept low to avoid associated harmful immunological responses.</p><p>These designs are effective in terms of lower chances of immunological exacerbation upon future RSV exposure in infants and ease of administration, which limits the viral infection to the upper respiratory tract [<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-11-00491" ref-type="bibr">66</xref>]. In terms of a systematic response, they induce mucosal immunity and humoral immune responses coupled with the passive immunity acquired by the mother. The main advantages associated with live-attenuated vaccination protocol are the easier intranasal administration route, the induction of first-hand immune responses, and the lower chances of exacerbated immune responses against pre-exposure to RSV [<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-11-00491" ref-type="bibr">65</xref>]. A disadvantage may include the need to acquire a balance between immunogenicity and attenuation adequacy [<xref rid="B64-vaccines-11-00491" ref-type="bibr">64</xref>]. Trials are underway to reduce the high rates of antibody titers in infants. This approach has been in clinical trials for a long time; some examples of ongoing clinical trials on live-attenuated vaccines were provided in <xref rid="vaccines-11-00491-t001" ref-type="table">Table 1</xref>.</p></sec><sec id="sec2dot2dot2-vaccines-11-00491"><title>2.2.2. Vector Delivery Systems against RSV</title><p>In this approach, some nonpathogenic virus vectors are used to express RSV proteinaceous candidates, such as the adenovirus vector system, in which portions of the RSV virus genome, such as F, N, G, and M2-1 proteins, are expressed [<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-11-00491" ref-type="bibr">14</xref>]. These vectors help modulate immunostimulatory functions in host bodies. These protein entities regulate T-cell-mediated responses by expressing the epitopes. They limit the cellular immune responses without causing insufficient viral attenuation [<xref rid="B69-vaccines-11-00491" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>]. Moreover, these vectors allow the adjuvant application to regulate better immunostimulatory profile management in clinical experiments. The virus vectors most used include adenovirus and modified vaccinia Ankara (MVA) [<xref rid="B63-vaccines-11-00491" ref-type="bibr">63</xref>].</p><p>A major advantage of a vector-based system is the induction of potent cellular and humoral response hosts and better safety profiles with no risk of insufficient attenuation as compared to live-attenuated vaccines, particularly in infants [<xref rid="B1-vaccines-11-00491" ref-type="bibr">1</xref>]. However, the concern about the required prior exposure to the vector and immunological memory may limit the immunostimulatory effect [<xref rid="B31-vaccines-11-00491" ref-type="bibr">31</xref>]. Moreover, the potential oncogenicity and pathogenicity associated with some virus vectors may also be major hurdles to be overcome for effective vaccine development. Vaccine trials based on these vector systems have exhibited moderate to self-limiting immunogenic responses at the site of injection with an overall efficacy in infants. However, further clinical applications are required for licensure [<xref rid="B31-vaccines-11-00491" ref-type="bibr">31</xref>,<xref rid="B71-vaccines-11-00491" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-11-00491" ref-type="bibr">72</xref>].</p></sec><sec id="sec2dot2dot3-vaccines-11-00491"><title>2.2.3. Protein/Peptide or Subunit Vaccines</title><p>In addition to live-attenuated and vector vaccine formulations, the protein or peptide or subunit vaccination approaches are effective vaccination candidates for RSV management [<xref rid="B73-vaccines-11-00491" ref-type="bibr">73</xref>]. Protein/peptide-based vaccines function like the RSV-neutralizing antibodies that are transferred passively from mother to fetus during pregnancy and, thus, cause the development of passive immunity in infants [<xref rid="B74-vaccines-11-00491" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-11-00491" ref-type="bibr">75</xref>]. Protein-based vaccines involve the use of whole viruses that are rendered inactivated or without the subunit antigens and viral particles [<xref rid="B75-vaccines-11-00491" ref-type="bibr">75</xref>]. These candidates are designed with different sizes and amounts of adjuvants to allow the partial release of viral particles over time [<xref rid="B74-vaccines-11-00491" ref-type="bibr">74</xref>]. One of the major advantages of peptide or protein-based vaccines is the effectiveness associated with material immunization via transplacental antibody transfer, which is beneficial for infants. However, the high risk of immune-stimulatory exacerbation may be a threat to infant application [<xref rid="B73-vaccines-11-00491" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-11-00491" ref-type="bibr">74</xref>]</p></sec><sec id="sec2dot2dot4-vaccines-11-00491"><title>2.2.4. mRNA Vaccines against RSV</title><p>Nucleic acid-based vaccines on mRNA and DNA have been in practice for many years. mRNA, however, is not preferably used as a tool of vaccine design due to the associated concerns of instability, poor efficacy, and potential to stimulate an excessive immune response, which is not needed for vaccination of RSV-infected individuals [<xref rid="B76-vaccines-11-00491" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-11-00491" ref-type="bibr">77</xref>]. These vaccines are transferred subcutaneously to the skin and muscle surfaces where they act via an antigenic expression system to deliver epitopes to be displayed T and B cells of the immune system [<xref rid="B59-vaccines-11-00491" ref-type="bibr">59</xref>,<xref rid="B78-vaccines-11-00491" ref-type="bibr">78</xref>]. Owing to the chance of exclusive immune responses, the current mRNA-based trials are mostly limited to adults and the elderly, and they require further work to establish efficacy in infants and children.</p></sec></sec><sec id="sec2dot3-vaccines-11-00491"><title>2.3. Immuno-Prophylaxis for RSV Management</title><p>Prophylaxis pertains to the immunomodulating, regulating, and stimulatory preparations that are developed to induce active and passive immunity generation in hosts [<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-11-00491" ref-type="bibr">51</xref>]. Certain RSV immunoglobulin preparations are carried out which contain monoclonal and polyclonal antibodies derived from donors that exhibit high RSV-neutralizing antibody titers [<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>,<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>]. These immunoprophylactic reduce the overall mortality and hospitalization rates in infants [<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>]. However, there are some issues associated with these immunologic preparations such as the need for long-term infusion and hospitalized supervision, high column dosages with the potential risk of excessive immune responses, and bloodborne pathogen development [<xref rid="B54-vaccines-11-00491" ref-type="bibr">54</xref>,<xref rid="B79-vaccines-11-00491" ref-type="bibr">79</xref>]. Similarly, they often make it impossible to apply other birth-associated vaccination drives such as against measles/mumps/rubella (MMR) vaccine or the smallpox vaccine [<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>,<xref rid="B80-vaccines-11-00491" ref-type="bibr">80</xref>]. Moreover, the issues of high cost and difficulty of manufacturing are also some issues challenges that need to be overcome for more profound immunoregulatory prophylaxis against RSV infection [<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot4-vaccines-11-00491"><title>2.4. Molecular Insights into the MOA of Antivirals against RSV</title><p>Antiviral therapies are quite a known field with almost similar technicalities and processes for different virus infections [<xref rid="B81-vaccines-11-00491" ref-type="bibr">81</xref>]. The drug development processes are quite similar and well acquainted. Moreover, the technical barriers associated with these processes have been systematically reduced with the upgradation of biotechnologies and bioinformatics tools. The well-known platforms of bioinformatics and in silico modules are now increasingly used for in vitro modeling and clinical experimentation [<xref rid="B81-vaccines-11-00491" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-11-00491" ref-type="bibr">82</xref>]. However, clinical experimentation and human-based models are still challenged owing to ethical health-related concerns. However, the available literature regarding the preclinical and early clinical data is immense for viral targets and holds hope for developing suitable antiviral candidates against RSV in the future [<xref rid="B57-vaccines-11-00491" ref-type="bibr">57</xref>,<xref rid="B83-vaccines-11-00491" ref-type="bibr">83</xref>].</p><p>The replication mechanism of RSV and its linked biological traits have been well studied, although gaps still exist regarding the exact nature of the infection. However, the available information is immense to design relevant and effective antiviral agents [<xref rid="B40-vaccines-11-00491" ref-type="bibr">40</xref>]. As elaborated earlier, the RSV genome encodes ~11 proteins, among which three majorly contribute to the viral envelope structure, namely, the glycoprotein (G), fusion (F), and small hydrophobic (SH) [<xref rid="B45-vaccines-11-00491" ref-type="bibr">45</xref>]. All these are utilized for the development of vaccine candidates (as explained earlier). Other proteins such as M2&#8211;1, M2-2, NS1, and NS2 are involved directly or indirectly in the viral replication procedure [<xref rid="B45-vaccines-11-00491" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-11-00491" ref-type="bibr">46</xref>]. The similar and conserved nature of some of these proteins suggests that antiviral agents could be manufactured with inhibitory potential across different virus species.</p><p>Similarly, the different surface characteristics of the host cell such as cell surface receptors and binding domains can also be utilized to design antiviral agents in the case of RSV [<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B23-vaccines-11-00491" ref-type="bibr">23</xref>]. For example, nucleolin is a receptor specific for RSV F protein recognition. It acts as a molecular shuttle to help move material across intracellular compartments. Thus, certain drugs are in trial phases that are repurposed for binding nucleolin (examples are provided in <xref rid="vaccines-11-00491-t002" ref-type="table">Table 2</xref>) [<xref rid="B78-vaccines-11-00491" ref-type="bibr">78</xref>]. Similarly, the various steps in virus replication and the viral particles involved in those steps can be potentiated as targets for antiviral designs. Factors such as glycosaminoglycans, the fractalkine receptor, RhoA, cell surface CX3CR1, and the aforementioned nucleolin, all of which contribute to viral attachment, entry, and replication steps, are good targets for antiviral therapies [<xref rid="B78-vaccines-11-00491" ref-type="bibr">78</xref>,<xref rid="B84-vaccines-11-00491" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-11-00491" ref-type="bibr">85</xref>].</p><p>Yet another approach is the use of Synthetic RNAi derivatives such as short RNA interference (siRNA) that function to specifically target and degrade mRNA function and deregulate the expression of virally encoded proteins [<xref rid="B86-vaccines-11-00491" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-11-00491" ref-type="bibr">87</xref>]. RNAi-based therapeutics have already shown efficacy in several other infections of genetic, cancerous, and viral origins [<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B88-vaccines-11-00491" ref-type="bibr">88</xref>]. Moreover, the inhibition of inflammatory agents in the host cell and regular inflammatory immune responses upon RSV infection are other effective mechanisms to control RSV pathogenesis. By targeting specific agents such as neutrophils (responsible for severe RSV-associated lung infection) an effective antiviral therapy can be proposed [<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B87-vaccines-11-00491" ref-type="bibr">87</xref>].</p><p>Additionally, targeting the virus surface molecules, such as F protein or G protein, could be an effective approach for the pharmacological inhibition of virus infection [<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>]. Some of the prophylaxis immunoglobulins are used to utilize these surface proteins, present them on antigen-presenting cells, and regulate immune responses through neutralizing antibody production [<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B89-vaccines-11-00491" ref-type="bibr">89</xref>]. Similar mechanisms are also used for vaccine development, as previously elaborated. Another important mechanism of antiviral development is to formulate antiviral agents that interfere with polymerase activity and, hence, avert virus replication and infection [<xref rid="B47-vaccines-11-00491" ref-type="bibr">47</xref>]. Such methods are accounted for as viral gene silencing. Moreover, by targeting the chemokines receptors such as CX3C and other related receptors, the RSV-induced pathological and inflammatory responses could be averted [<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B90-vaccines-11-00491" ref-type="bibr">90</xref>]. Furthermore, the combined application of host-directed inhibiting agents and antiviral agents is another attractive approach for designing effective therapeutics, but there is a need to keep an account of cellular toxicity [<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>,<xref rid="B13-vaccines-11-00491" ref-type="bibr">13</xref>].</p><p>Most of the described antiviral approaches involve the consideration of viral loads. However, there is conflicting inference as to whether the viral load correlates with the clinical severity of RSV infecting humans or not [<xref rid="B17-vaccines-11-00491" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>,<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>,<xref rid="B91-vaccines-11-00491" ref-type="bibr">91</xref>]. This is because different studies have devised different inferences. These data suggest that a combinational approach of antiviral and anti-inflammatory agents with immune-regulatory prophylaxis-based treatment could be better against overall pathogenesis. A combined effect will regulate viral and host factors, as well as immune responses in humans. Therefore, future viral therapies should concentrate more on combination, prime boosting, and co-application approaches [<xref rid="B18-vaccines-11-00491" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-11-00491" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>,<xref rid="B54-vaccines-11-00491" ref-type="bibr">54</xref>,<xref rid="B92-vaccines-11-00491" ref-type="bibr">92</xref>]. Some important antiviral strategies, along with particular examples and clinical trials, are explained briefly in <xref rid="vaccines-11-00491-t002" ref-type="table">Table 2</xref>.
<table-wrap position="float" id="vaccines-11-00491-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-11-00491-t002_Table 2</object-id><label>Table 2</label><caption><p>Antiviral agents and therapeutics in clinical development against RSV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sr. No. </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antiviral and Therapeutics Approach</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Candidates under Clinical Trials </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Viral cellular entity inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Aptamers (nucleolin-binding agents)</p></list-item><list-item><p>(G)-rich oligonucleotide (nucleolin inhibitor)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B5-vaccines-11-00491" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-11-00491" ref-type="bibr">6</xref>,<xref rid="B30-vaccines-11-00491" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-11-00491" ref-type="bibr">31</xref>,<xref rid="B56-vaccines-11-00491" ref-type="bibr">56</xref>,<xref rid="B62-vaccines-11-00491" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-11-00491" ref-type="bibr">63</xref>,<xref rid="B80-vaccines-11-00491" ref-type="bibr">80</xref>,<xref rid="B93-vaccines-11-00491" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-11-00491" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-11-00491" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-11-00491" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-11-00491" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-11-00491" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-11-00491" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-11-00491" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-11-00491" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-11-00491" ref-type="bibr">102</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Host virus fusion inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>GS-5806 (presatovir)</p></list-item><list-item><p>VP-14637 (renamed to MDT-637and JNJ-2408068)</p></list-item><list-item><p>ALX-0171</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>,<xref rid="B23-vaccines-11-00491" ref-type="bibr">23</xref>,<xref rid="B29-vaccines-11-00491" ref-type="bibr">29</xref>,<xref rid="B48-vaccines-11-00491" ref-type="bibr">48</xref>,<xref rid="B70-vaccines-11-00491" ref-type="bibr">70</xref>,<xref rid="B100-vaccines-11-00491" ref-type="bibr">100</xref>,<xref rid="B103-vaccines-11-00491" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-11-00491" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-11-00491" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-11-00491" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-11-00491" ref-type="bibr">107</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polymerase inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>ALS-8176</p></list-item><list-item><p>T-705 (favipiravir)</p></list-item><list-item><p>RSV-604 (A-60444)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B47-vaccines-11-00491" ref-type="bibr">47</xref>,<xref rid="B68-vaccines-11-00491" ref-type="bibr">68</xref>,<xref rid="B108-vaccines-11-00491" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-11-00491" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-11-00491" ref-type="bibr">110</xref>,<xref rid="B111-vaccines-11-00491" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-11-00491" ref-type="bibr">112</xref>,<xref rid="B113-vaccines-11-00491" ref-type="bibr">113</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nucleoside analog inhibitors</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Ribavirin (NA inhibitor of RNA synthesis)</p></list-item><list-item><p>ALS-008176</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-vaccines-11-00491" ref-type="bibr">9</xref>,<xref rid="B11-vaccines-11-00491" ref-type="bibr">11</xref>,<xref rid="B22-vaccines-11-00491" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-11-00491" ref-type="bibr">23</xref>,<xref rid="B47-vaccines-11-00491" ref-type="bibr">47</xref>], </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Synthetic RNAi derivatives</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>ALN-RSV01(siRNA against the RSV nucleocapsid (N) protein)</p></list-item><list-item><p>ALS-008176 (NA)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-vaccines-11-00491" ref-type="bibr">49</xref>,<xref rid="B88-vaccines-11-00491" ref-type="bibr">88</xref>,<xref rid="B106-vaccines-11-00491" ref-type="bibr">106</xref>,<xref rid="B114-vaccines-11-00491" ref-type="bibr">114</xref>,<xref rid="B115-vaccines-11-00491" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-11-00491" ref-type="bibr">116</xref>],</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting inflammatory molecules/anti-inflammatory molecules</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Danirixin (GSK1325756)</p></list-item><list-item><p>RV568, (narrow spectrum kinase inhibitor)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B20-vaccines-11-00491" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-11-00491" ref-type="bibr">21</xref>,<xref rid="B27-vaccines-11-00491" ref-type="bibr">27</xref>,<xref rid="B50-vaccines-11-00491" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-11-00491" ref-type="bibr">51</xref>,<xref rid="B54-vaccines-11-00491" ref-type="bibr">54</xref>,<xref rid="B58-vaccines-11-00491" ref-type="bibr">58</xref>,<xref rid="B79-vaccines-11-00491" ref-type="bibr">79</xref>],</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prophylactics and immunoregulators</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>MEDI 557 (recombinant human monoclonal antibody)</p></list-item><list-item><p>MEDI 8897 (human RSV monoclonal antibody)</p></list-item><list-item><p>RI-001 (polyclonal antibody)</p></list-item><list-item><p>Motavizumab (MEDI-524), derived from palivizumab</p></list-item><list-item><p>Trivalent nanobody ALX-0171</p></list-item><list-item><p>D25 RSV antibody (against F glycoproteins)</p></list-item><list-item><p>(RSV-IVIG, RespiGam) intravenous immunoglobulin</p></list-item><list-item><p>Palivizumab (humanized monoclonal IgG1 antibody)</p></list-item><list-item><p>ALX-0171 (a nanobody preparation)</p></list-item><list-item><p>REGN2222, (human monoclonal IgG1 antibody against RSV-F)</p></list-item><list-item><p>MEDI-557 (derived from motavizumab)</p></list-item><list-item><p>MEDI-8897, derived from D25-, an anti-RSV F MAb)</p></list-item></list></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B106-vaccines-11-00491" ref-type="bibr">106</xref>,<xref rid="B117-vaccines-11-00491" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-11-00491" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-11-00491" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-11-00491" ref-type="bibr">120</xref>,<xref rid="B121-vaccines-11-00491" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-11-00491" ref-type="bibr">122</xref>,<xref rid="B123-vaccines-11-00491" ref-type="bibr">123</xref>,<xref rid="B124-vaccines-11-00491" ref-type="bibr">124</xref>,<xref rid="B125-vaccines-11-00491" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-11-00491" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-11-00491" ref-type="bibr">127</xref>,<xref rid="B128-vaccines-11-00491" ref-type="bibr">128</xref>]</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec2dot5-vaccines-11-00491"><title>2.5. RSV Infection, Vulnerability of Infants, and the Vaccination Efforts</title><p>As elaborated earlier, RSV majorly affects infants; thus, the major hurdle in RSV vaccine development is the vulnerable nature of the immune system in infants and children [<xref rid="B129-vaccines-11-00491" ref-type="bibr">129</xref>]. Vaccination efforts to prevent RSV infection in infants have mainly resulted in kids becoming sick, according to recent research [<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>]. These findings have also helped provide essential clues regarding safe and effective vaccines and therapeutic development against RSV [<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>]. The earlier vaccination trials that date back to the 1960s confined future vaccination campaigns owing to the hospitalization cases that arose in vaccinated children [<xref rid="B129-vaccines-11-00491" ref-type="bibr">129</xref>]. In those trials, inactivated virus particle-based vaccines were utilized. Approximately 8% of children became hospitalized following vaccination, and two died of infection [<xref rid="B128-vaccines-11-00491" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-11-00491" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>].</p><p>It remains unclear whether improper inactivation or the chemical formalin (used for inactivation) resulted in morbidities in those children. The scientific rigor in later years helped to overcome this confusion [<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>]. Researchers provided information about why the vaccine caused illnesses such as enhanced respiratory disease (ERD). The resulting causes indicated that the children's immune system (antibodies) was not binding strongly enough with the inactivated virus particles (antigens) to produce effective and protective immune responses [<xref rid="B128-vaccines-11-00491" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-11-00491" ref-type="bibr">129</xref>,<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>]. The antibodies were found to be dragging the dead viral particles with them, which resulted in triggered immune responses from other cells of the immune system in those patients [<xref rid="B129-vaccines-11-00491" ref-type="bibr">129</xref>]. A better vaccine candidate or therapeutic agent (based on attenuated viruses) may be required in the future to trigger stronger immune responses [<xref rid="B100-vaccines-11-00491" ref-type="bibr">100</xref>,<xref rid="B101-vaccines-11-00491" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-11-00491" ref-type="bibr">102</xref>]. Thus, there is a need to follow appropriate procedures and coordinate clinical research trials to develop successful therapeutics and vaccines against RSV infection in the coming years [<xref rid="B130-vaccines-11-00491" ref-type="bibr">130</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec3-vaccines-11-00491"><title>3. Conclusions</title><p>Respiratory syncytial virus (RSV) remains a pathogenic threat to immunocompromised patients worldwide. Despite enormous insight into RSV pathology, some data regarding the pathogenesis remain unaddressed, thus necessitating further exploration for future antiviral development. Only a limited number of drugs or vaccines have been approved against RSV, and they also exhibit some limitations for global clinical deployment unlike other viral infections and therapeutic developments. Limited data are available regarding specific therapeutics and licensed vaccines for controlling the associated healthcare dilemma. Most of these trials are stuck in clinical phase 1 or 2; thus, further clinical practices are necessary for licensure and approval. The traditional strategies of vaccines and antiviral agents are in the redevelopment and upgradation phase. Importance should also be directed toward novel approaches such as those involving nanotechnology, immunomodulators, molecular inhibitors, gene silencers, and siRNA. Researchers will require a profoundly integrated and well-knitted effort, involving bioinformaticians and pharmacologists, to propose an effective understanding of RSV pathogenesis and clinical practice of novel vaccines, prophylactics, and antiviral therapeutics. The role of healthcare authorities such as the FDA, WHO, and CDC will also remain important for figuring out ways for improvising clinical experiments through the provision of funding, as well as appropriate recommendations for the community-level application of approved and licensed drugs. Moreover, industrial involvement, community acceptance, and wide-spectrum application are some other challenges that remain to be effective and immediately dealt with to prevent further deaths from RSV in the future.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, S.M. and YW.; methodology, S.M., T.A., K.M. and Y.W.; validation, S.M., T.A. and K.M.; formal analysis, S.M., K.M. and Y.W.; resources, K.M. and Y.W.; data curation, S.M. T.A., K.M. and Y.W.; writing&#8212;original draft preparation, S.M.; writing&#8212;review and editing, S.M., T.A., K.M. and Y.W.; supervision, Y.W.; project administration, Y.W.; funding acquisition, K.M. and Y.W. All authors read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDC</td><td align="left" valign="middle" rowspan="1" colspan="1">Centers for Disease Control and Prevention</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CXC</td><td align="left" valign="middle" rowspan="1" colspan="1">C chemokine family</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">F</td><td align="left" valign="middle" rowspan="1" colspan="1">fusion protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">G</td><td align="left" valign="middle" rowspan="1" colspan="1">glycoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L</td><td align="left" valign="middle" rowspan="1" colspan="1">polymerase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LAV</td><td align="left" valign="middle" rowspan="1" colspan="1">live-attenuated vaccine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LRTI</td><td align="left" valign="middle" rowspan="1" colspan="1">lower-respiratory-tract infection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M</td><td align="left" valign="middle" rowspan="1" colspan="1">matrix protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M2</td><td align="left" valign="middle" rowspan="1" colspan="1">regulatory protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAbs</td><td align="left" valign="middle" rowspan="1" colspan="1">monoclonal antibodies</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MVA</td><td align="left" valign="middle" rowspan="1" colspan="1">modified vaccinia Ankara</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">N</td><td align="left" valign="middle" rowspan="1" colspan="1">nucleoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P</td><td align="left" valign="middle" rowspan="1" colspan="1">phosphoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RhoA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ras homolog family member A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RNAi</td><td align="left" valign="middle" rowspan="1" colspan="1">RNA interference</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RSV</td><td align="left" valign="middle" rowspan="1" colspan="1">respiratory syncytial virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SH</td><td align="left" valign="middle" rowspan="1" colspan="1">small hydrophobic protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SNPs</td><td align="left" valign="middle" rowspan="1" colspan="1">single-nucleotide polymorphisms</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VLPs</td><td align="left" valign="middle" rowspan="1" colspan="1">virus-like particles</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">WHO</td><td align="left" valign="middle" rowspan="1" colspan="1">World Health Organization</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-vaccines-11-00491"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>G.</given-names></name><name name-style="western"><surname>Landgrave</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Thompson</surname><given-names>R.</given-names></name></person-group><article-title>Respiratory syncytial virus: Current and emerging treatment options</article-title><source>Clin. Outcomes Res.</source><year>2014</year><volume>6</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.2147/CEOR.S60710</pub-id><pub-id pub-id-type="pmid">24812523</pub-id><pub-id pub-id-type="pmcid">PMC4008286</pub-id></element-citation></ref><ref id="B2-vaccines-11-00491"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borchers</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name></person-group><article-title>Respiratory syncytial virus&#8212;A comprehensive review</article-title><source>Clin. Rev. Allergy Immunol.</source><year>2013</year><volume>45</volume><fpage>331</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1007/s12016-013-8368-9</pub-id><pub-id pub-id-type="pmid">23575961</pub-id><pub-id pub-id-type="pmcid">PMC7090643</pub-id></element-citation></ref><ref id="B3-vaccines-11-00491"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jorquera</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name></person-group><article-title>Respiratory syncytial virus: Prospects for new and emerging therapeutics</article-title><source>Expert Rev. Respir. Med.</source><year>2017</year><volume>11</volume><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1080/17476348.2017.1338567</pub-id><pub-id pub-id-type="pmid">28574729</pub-id></element-citation></ref><ref id="B4-vaccines-11-00491"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ramilo</surname><given-names>O.</given-names></name></person-group><article-title>Respiratory syncytial virus: How, why and what to do</article-title><source>J. Infect.</source><year>2014</year><volume>68</volume><fpage>S115</fpage><lpage>S118</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2013.09.021</pub-id><pub-id pub-id-type="pmid">24171820</pub-id></element-citation></ref><ref id="B5-vaccines-11-00491"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Storey</surname><given-names>S.</given-names></name></person-group><article-title>Respiratory syncytial virus market</article-title><source>Nat. Rev. Drug. Discov.</source><year>2010</year><volume>9</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1038/nrd3075</pub-id><pub-id pub-id-type="pmid">20043025</pub-id></element-citation></ref><ref id="B6-vaccines-11-00491"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Englund</surname><given-names>J.A.</given-names></name></person-group><article-title>Respiratory Syncytial Virus Disease: Prevention and Treatment</article-title><source>Challenges and Opportunities for Respiratory Syncytial Virus Vaccines</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2013</year><fpage>235</fpage><lpage>258</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-38919-1_12</pub-id><pub-id pub-id-type="pmid">24362693</pub-id></element-citation></ref><ref id="B7-vaccines-11-00491"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welliver</surname><given-names>R.C.</given-names></name></person-group><article-title>Pharmacotherapy of respiratory syncytial virus infection</article-title><source>Curr. Opin. Pharmacol.</source><year>2010</year><volume>10</volume><fpage>289</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2010.04.013</pub-id><pub-id pub-id-type="pmid">20493773</pub-id></element-citation></ref><ref id="B8-vaccines-11-00491"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.</given-names></name></person-group><article-title>Respiratory syncytial virus infection in adult populations</article-title><source>Infect. Disord. -Drug Targets (Former. Curr. Drug Targets-Infect. Disord.)</source><year>2012</year><volume>12</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.2174/187152612800100116</pub-id><pub-id pub-id-type="pmid">22335500</pub-id></element-citation></ref><ref id="B9-vaccines-11-00491"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Battles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Langedijk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hollenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaiwatpongsakorn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kwantenn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vranckx</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vink</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jaensch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jonckers</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Molecular mechanism of respiratory syncytial virus fusion inhibitors</article-title><source>Nat. Chem. Biol.</source><year>2016</year><volume>12</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1982</pub-id><pub-id pub-id-type="pmid">26641933</pub-id><pub-id pub-id-type="pmcid">PMC4731865</pub-id></element-citation></ref><ref id="B10-vaccines-11-00491"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Argentiero</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fainardi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pisi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name></person-group><article-title>Role of respiratory syncytial virus in pediatric pneumonia</article-title><source>Microorganisms</source><year>2020</year><volume>8</volume><elocation-id>2048</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms8122048</pub-id><pub-id pub-id-type="pmid">33371276</pub-id><pub-id pub-id-type="pmcid">PMC7766387</pub-id></element-citation></ref><ref id="B11-vaccines-11-00491"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roymans</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alnajjar</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Battles</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sitthicharoenchai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Furmanova-Hollenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rigaux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Van den Berg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwanten</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Ginderen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Verheyen</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>167</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00170-x</pub-id><pub-id pub-id-type="pmid">28761099</pub-id><pub-id pub-id-type="pmcid">PMC5537225</pub-id></element-citation></ref><ref id="B12-vaccines-11-00491"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Blau</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Feikin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Omer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.F.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>2047</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00478-0</pub-id><pub-id pub-id-type="pmid">35598608</pub-id><pub-id pub-id-type="pmcid">PMC7613574</pub-id></element-citation></ref><ref id="B13-vaccines-11-00491"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Dormitzer</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Nokes</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name></person-group><article-title>Strategic priorities for respiratory syncytial virus (RSV) vaccine development</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>B209</fpage><lpage>B215</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.106</pub-id><pub-id pub-id-type="pmid">23598484</pub-id><pub-id pub-id-type="pmcid">PMC3919153</pub-id></element-citation></ref><ref id="B14-vaccines-11-00491"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Proesmans</surname><given-names>M.</given-names></name></person-group><article-title>New therapies for acute RSV infections: Where are we?</article-title><source>Eur. J. Pediatr.</source><year>2019</year><volume>178</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1007/s00431-018-03310-7</pub-id><pub-id pub-id-type="pmid">30610420</pub-id></element-citation></ref><ref id="B15-vaccines-11-00491"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramilo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lagos</surname><given-names>R.</given-names></name><name name-style="western"><surname>S&#225;ez-Llorens</surname><given-names>X.</given-names></name><name name-style="western"><surname>Suzich</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>M.P.</given-names></name><collab>Motavizumab Study Group</collab></person-group><article-title>Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness</article-title><source>Pediatr. Infect Dis. J.</source><year>2014</year><volume>33</volume><fpage>703</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000000240</pub-id><pub-id pub-id-type="pmid">24356256</pub-id></element-citation></ref><ref id="B16-vaccines-11-00491"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Beeler</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.N.</given-names></name></person-group><article-title>Summary of the Vaccines and Related Biological Products Advisory Committee meeting held to consider the evaluation of vaccine candidates for preventing respiratory syncytial virus disease in RSV-na&#239;ve infants</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.10.048</pub-id><pub-id pub-id-type="pmid">31706809</pub-id></element-citation></ref><ref id="B17-vaccines-11-00491"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coultas</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group><article-title>Respiratory syncytial virus (RSV): A scourge from infancy to old age</article-title><source>Thorax</source><year>2019</year><volume>74</volume><fpage>986</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2018-212212</pub-id><pub-id pub-id-type="pmid">31383776</pub-id></element-citation></ref><ref id="B18-vaccines-11-00491"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalergis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>G&#225;lvez</surname><given-names>N.M.S.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bohmwald</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>S.M.</given-names></name></person-group><article-title>Pharmacological management of human respiratory syncytial virus infection</article-title><source>Expert Opin. Pharmacother.</source><year>2020</year><volume>21</volume><fpage>2293</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1080/14656566.2020.1806821</pub-id><pub-id pub-id-type="pmid">32808830</pub-id></element-citation></ref><ref id="B19-vaccines-11-00491"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aloy</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Estrany</surname><given-names>X.C.</given-names></name><name name-style="western"><surname>de la Seneo</surname><given-names>C.D.E.</given-names></name></person-group><article-title>Update of recommendations on the use of palivizumab as prophylaxis in RSV infections</article-title><source>An. De Pediatr&#237;a (Engl. Ed.)</source><year>2015</year><volume>82</volume><fpage>199.e1</fpage><lpage>199.e2</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anpedi.2014.10.004</pub-id><pub-id pub-id-type="pmid">25453311</pub-id></element-citation></ref><ref id="B20-vaccines-11-00491"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Beek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Paes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bont</surname><given-names>L.</given-names></name></person-group><article-title>Increased risk of RSV infection in children with down&#8217;s syndrome: Clinical implementation of prophylaxis in the european union</article-title><source>Clin. Dev. Immunol.</source><year>2013</year><volume>2013</volume><fpage>801581</fpage><pub-id pub-id-type="doi">10.1155/2013/801581</pub-id><pub-id pub-id-type="pmid">23878586</pub-id><pub-id pub-id-type="pmcid">PMC3708408</pub-id></element-citation></ref><ref id="B21-vaccines-11-00491"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fearns</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deval</surname><given-names>J.</given-names></name></person-group><article-title>New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase</article-title><source>Antivir. Res.</source><year>2016</year><volume>134</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.08.006</pub-id><pub-id pub-id-type="pmid">27575793</pub-id></element-citation></ref><ref id="B22-vaccines-11-00491"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mackman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Perron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cihlar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Eisenberg</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strickley</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Chien</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><fpage>4889</fpage><lpage>4900</lpage><pub-id pub-id-type="doi">10.1128/AAC.00487-15</pub-id><pub-id pub-id-type="pmid">26055364</pub-id><pub-id pub-id-type="pmcid">PMC4505261</pub-id></element-citation></ref><ref id="B23-vaccines-11-00491"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeVincenzo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tait</surname><given-names>D.</given-names></name><name name-style="western"><surname>Efthimiou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cockerill</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01884-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.01884-19</pub-id><pub-id pub-id-type="pmid">31712214</pub-id><pub-id pub-id-type="pmcid">PMC6985722</pub-id></element-citation></ref><ref id="B24-vaccines-11-00491"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilia</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Bergonzi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Guccione</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manconi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fadda</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sinico</surname><given-names>C.</given-names></name></person-group><article-title>Vesicles and micelles: Two versatile vectors for the delivery of natural products</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2016</year><volume>32</volume><fpage>241</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.jddst.2015.09.007</pub-id></element-citation></ref><ref id="B25-vaccines-11-00491"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name></person-group><article-title>Biological challenges and technological opportunities for respiratory syncytial virus vaccine development</article-title><source>Immunol. Rev.</source><year>2011</year><volume>239</volume><fpage>149</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00972.x</pub-id><pub-id pub-id-type="pmid">21198670</pub-id><pub-id pub-id-type="pmcid">PMC3023887</pub-id></element-citation></ref><ref id="B26-vaccines-11-00491"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>L.M.</given-names></name></person-group><article-title>Progress and challenges in RSV prophylaxis and vaccine development</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>208</volume><fpage>S177</fpage><lpage>S183</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit512</pub-id><pub-id pub-id-type="pmid">24265476</pub-id></element-citation></ref><ref id="B27-vaccines-11-00491"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicholson</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>F.M.</given-names></name></person-group><article-title>A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children</article-title><source>Clin. Ther.</source><year>2018</year><volume>40</volume><fpage>1268</fpage><lpage>1281</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2018.06.014</pub-id><pub-id pub-id-type="pmid">30077340</pub-id></element-citation></ref><ref id="B28-vaccines-11-00491"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaird</surname><given-names>O.E.</given-names></name><name name-style="western"><surname>Freifeld</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ison</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Theodoropoulos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Razonable</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Alangaden</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Current practices for treating respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative</article-title><source>Transpl. Infect. Dis.</source><year>2016</year><volume>18</volume><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/tid.12510</pub-id><pub-id pub-id-type="pmid">26923867</pub-id><pub-id pub-id-type="pmcid">PMC7169710</pub-id></element-citation></ref><ref id="B29-vaccines-11-00491"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bawage</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Pillai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.R.</given-names></name></person-group><article-title>Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus</article-title><source>Adv. Virol.</source><year>2013</year><volume>2013</volume><fpage>595768</fpage><pub-id pub-id-type="doi">10.1155/2013/595768</pub-id><pub-id pub-id-type="pmid">24382964</pub-id><pub-id pub-id-type="pmcid">PMC3872095</pub-id></element-citation></ref><ref id="B30-vaccines-11-00491"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bates</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Utley</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Schief</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.E.</given-names></name></person-group><article-title>Reversion of Somatic Mutations of the Respiratory Syncytial Virus&#8211;Specific Human Monoclonal Antibody Fab19 reveal a direct relationship between association rate and neutralizing potency</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>3732</fpage><lpage>3739</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202964</pub-id><pub-id pub-id-type="pmid">23455501</pub-id><pub-id pub-id-type="pmcid">PMC3608519</pub-id></element-citation></ref><ref id="B31-vaccines-11-00491"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krilov</surname><given-names>L.R.</given-names></name></person-group><article-title>Respiratory syncytial virus disease: Update on treatment and prevention</article-title><source>Expert Rev. Anti. Infect. Ther.</source><year>2011</year><volume>9</volume><fpage>27</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1586/eri.10.140</pub-id><pub-id pub-id-type="pmid">21171875</pub-id></element-citation></ref><ref id="B32-vaccines-11-00491"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mejias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramilo</surname><given-names>O.</given-names></name></person-group><article-title>New options for treating respiratory syncytial virus disease</article-title><source>J. Infect.</source><year>2015</year><volume>71</volume><fpage>S80</fpage><lpage>S87</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2015.04.025</pub-id><pub-id pub-id-type="pmid">25922289</pub-id></element-citation></ref><ref id="B33-vaccines-11-00491"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domachowske</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>M.</given-names></name></person-group><article-title>The future of respiratory syncytial virus disease prevention and treatment</article-title><source>Infect. Dis. Ther.</source><year>2021</year><volume>10</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s40121-020-00383-6</pub-id><pub-id pub-id-type="pmcid">PMC7926075</pub-id><pub-id pub-id-type="pmid">33656652</pub-id></element-citation></ref><ref id="B34-vaccines-11-00491"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickles</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>DeVincenzo</surname><given-names>J.P.</given-names></name></person-group><article-title>Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis</article-title><source>J. Pathol.</source><year>2015</year><volume>235</volume><fpage>266</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1002/path.4462</pub-id><pub-id pub-id-type="pmid">25302625</pub-id><pub-id pub-id-type="pmcid">PMC5638117</pub-id></element-citation></ref><ref id="B35-vaccines-11-00491"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derscheid</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ackermann</surname><given-names>M.R.</given-names></name></person-group><article-title>Perinatal lamb model of respiratory syncytial virus (RSV) infection</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>2359</fpage><lpage>2378</lpage><pub-id pub-id-type="doi">10.3390/v4102359</pub-id><pub-id pub-id-type="pmid">23202468</pub-id><pub-id pub-id-type="pmcid">PMC3497056</pub-id></element-citation></ref><ref id="B36-vaccines-11-00491"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hindiyeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolet</surname><given-names>L.</given-names></name><name name-style="western"><surname>Regev</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sherbany</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yaary</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mendelson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mandelboim</surname><given-names>M.</given-names></name></person-group><article-title>Epidemiological changes of respiratory syncytial virus (RSV) infections in Israel</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e90515</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0090515</pub-id><pub-id pub-id-type="pmid">24594694</pub-id><pub-id pub-id-type="pmcid">PMC3940902</pub-id></element-citation></ref><ref id="B37-vaccines-11-00491"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chirkova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.J.</given-names></name></person-group><article-title>Biology of infection and disease pathogenesis to guide RSV vaccine development</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>1675</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.01675</pub-id><pub-id pub-id-type="pmid">31402910</pub-id><pub-id pub-id-type="pmcid">PMC6677153</pub-id></element-citation></ref><ref id="B38-vaccines-11-00491"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name></person-group><article-title>Immunological goals for respiratory syncytial virus vaccine development</article-title><source>Curr. Opin. Immunol.</source><year>2019</year><volume>59</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2019.03.005</pub-id><pub-id pub-id-type="pmid">31029910</pub-id></element-citation></ref><ref id="B39-vaccines-11-00491"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Hultquist</surname><given-names>J.F.</given-names></name></person-group><article-title>Clinical and biological consequences of respiratory syncytial virus genetic diversity</article-title><source>Ther. Adv. Infect. Dis.</source><year>2022</year><volume>9</volume><fpage>20499361221128092</fpage><pub-id pub-id-type="doi">10.1177/20499361221128091</pub-id><pub-id pub-id-type="pmcid">PMC9549189</pub-id><pub-id pub-id-type="pmid">36225856</pub-id></element-citation></ref><ref id="B40-vaccines-11-00491"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name></person-group><article-title>Vaccine development for respiratory syncytial virus</article-title><source>Curr. Opin. Virol.</source><year>2017</year><volume>23</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2017.03.012</pub-id><pub-id pub-id-type="pmid">28525878</pub-id><pub-id pub-id-type="pmcid">PMC5653266</pub-id></element-citation></ref><ref id="B41-vaccines-11-00491"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirbaghaee</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name></person-group><article-title>Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems</article-title><source>Biopolymers</source><year>2016</year><volume>105</volume><fpage>113</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1002/bip.22759</pub-id><pub-id pub-id-type="pmid">26509554</pub-id><pub-id pub-id-type="pmcid">PMC7161881</pub-id></element-citation></ref><ref id="B42-vaccines-11-00491"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandya</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Savchenko</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Stobart</surname><given-names>C.C.</given-names></name></person-group><article-title>A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences</article-title><source>Pathogens</source><year>2019</year><volume>8</volume><elocation-id>67</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8020067</pub-id><pub-id pub-id-type="pmid">31117229</pub-id><pub-id pub-id-type="pmcid">PMC6631838</pub-id></element-citation></ref><ref id="B43-vaccines-11-00491"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pemberton</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stoycheva</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Dyatkina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Symons</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Deval</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Activation pathway of a nucleoside analog inhibiting respiratory syncytial virus polymerase</article-title><source>ACS Chem. Biol.</source><year>2017</year><volume>12</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1021/acschembio.6b00788</pub-id><pub-id pub-id-type="pmid">28103684</pub-id></element-citation></ref><ref id="B44-vaccines-11-00491"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>McAuliffe</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wachter</surname><given-names>L.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Suzich</surname><given-names>J.A.</given-names></name></person-group><article-title>Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): Effects on RSV susceptibility to palivizumab</article-title><source>J. Infect. Dis.</source><year>2012</year><volume>205</volume><fpage>635</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir790</pub-id><pub-id pub-id-type="pmid">22184728</pub-id></element-citation></ref><ref id="B45-vaccines-11-00491"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>H.</given-names></name><name name-style="western"><surname>Domachowske</surname><given-names>J.</given-names></name></person-group><article-title>Inflammatory responses to respiratory syncytial virus (RSV) infection and the development of immunomodulatory pharmacotherapeutics</article-title><source>Curr. Med. Chem.</source><year>2012</year><volume>19</volume><fpage>1424</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.2174/092986712799828346</pub-id><pub-id pub-id-type="pmid">22360479</pub-id><pub-id pub-id-type="pmcid">PMC3422571</pub-id></element-citation></ref><ref id="B46-vaccines-11-00491"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paes</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>I.</given-names></name><name name-style="western"><surname>Banerji</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanct&#244;t</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>J.M.</given-names></name></person-group><article-title>A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice</article-title><source>Can. Respir. J.</source><year>2011</year><volume>18</volume><fpage>e10</fpage><lpage>e19</lpage><pub-id pub-id-type="doi">10.1155/2011/493056</pub-id><pub-id pub-id-type="pmid">21499597</pub-id><pub-id pub-id-type="pmcid">PMC3084427</pub-id></element-citation></ref><ref id="B47-vaccines-11-00491"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausen</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Zaffiri</surname><given-names>L.</given-names></name></person-group><article-title>Infection prophylaxis and management of viral infection</article-title><source>Ann. Transl. Med.</source><year>2020</year><volume>8</volume><fpage>415</fpage><pub-id pub-id-type="doi">10.21037/atm.2019.11.85</pub-id><pub-id pub-id-type="pmid">32355859</pub-id><pub-id pub-id-type="pmcid">PMC7186616</pub-id></element-citation></ref><ref id="B48-vaccines-11-00491"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garlapati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brownlie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Latimer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Drunen Littel-van den Hurk</surname><given-names>S.</given-names></name></person-group><article-title>Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>5206</fpage><lpage>5214</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.011</pub-id><pub-id pub-id-type="pmid">22713718</pub-id></element-citation></ref><ref id="B49-vaccines-11-00491"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Latimer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gerdts</surname><given-names>V.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>A.</given-names></name></person-group><article-title>Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation</article-title><source>J. Gen. Virol.</source><year>2014</year><volume>95</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1099/vir.0.058461-0</pub-id><pub-id pub-id-type="pmid">24136365</pub-id></element-citation></ref><ref id="B50-vaccines-11-00491"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bollani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baraldi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chirico</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dotta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lanari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Vecchio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boldrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paolillo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Fabio</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)</article-title><source>Ital. J. Pediatr.</source><year>2015</year><volume>41</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s13052-015-0203-x</pub-id><pub-id pub-id-type="pmid">26670908</pub-id><pub-id pub-id-type="pmcid">PMC4681171</pub-id></element-citation></ref><ref id="B51-vaccines-11-00491"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>S.</given-names></name><name name-style="western"><surname>Varadarajan</surname><given-names>R.</given-names></name></person-group><article-title>Broadly neutralizing antibodies for therapy of viral infections</article-title><source>Antib. Technol. J.</source><year>2016</year><volume>6</volume><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B52-vaccines-11-00491"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mejias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garcia-Maurino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rodriguez-Fernandez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peeples</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ramilo</surname><given-names>O.</given-names></name></person-group><article-title>Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>496</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.09.026</pub-id><pub-id pub-id-type="pmid">27692523</pub-id><pub-id pub-id-type="pmcid">PMC5183505</pub-id></element-citation></ref><ref id="B53-vaccines-11-00491"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blair</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>C.</given-names></name></person-group><article-title>Current landscape of antiviral drug discovery</article-title><source>F1000Res</source><year>2016</year><volume>5</volume><pub-id pub-id-type="doi">10.12688/f1000research.7665.1</pub-id><pub-id pub-id-type="pmid">26962437</pub-id><pub-id pub-id-type="pmcid">PMC4765712</pub-id></element-citation></ref><ref id="B54-vaccines-11-00491"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>A.-M.</given-names></name></person-group><article-title>The Development of mRNA Vaccines for Infectious Diseases: Recent Updates</article-title><source>Infect. Drug Resist.</source><year>2021</year><volume>14</volume><fpage>5271</fpage><lpage>5285</lpage><pub-id pub-id-type="pmid">34916811</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S341694</pub-id><pub-id pub-id-type="pmcid">PMC8668227</pub-id></element-citation></ref><ref id="B55-vaccines-11-00491"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Novel antigens for RSV vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2015</year><volume>35</volume><fpage>30</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2015.04.005</pub-id><pub-id pub-id-type="pmid">26070108</pub-id><pub-id pub-id-type="pmcid">PMC4553118</pub-id></element-citation></ref><ref id="B56-vaccines-11-00491"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Beeler</surname><given-names>J.A.</given-names></name></person-group><article-title>Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>4843</fpage><lpage>4849</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.07.057</pub-id><pub-id pub-id-type="pmid">27566900</pub-id></element-citation></ref><ref id="B57-vaccines-11-00491"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guvenel</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.M.</given-names></name></person-group><article-title>Current concepts and progress in RSV vaccine development</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.878653</pub-id><pub-id pub-id-type="pmid">24405366</pub-id><pub-id pub-id-type="pmcid">PMC7612829</pub-id></element-citation></ref><ref id="B58-vaccines-11-00491"><label>58.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name></person-group><article-title>Live-Attenuated Respiratory Syncytial Virus Vaccines</article-title><source>Challenges and Opportunities for Respiratory Syncytial Virus Vaccines</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2013</year><fpage>259</fpage><lpage>284</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-38919-1_13</pub-id><pub-id pub-id-type="pmcid">PMC4794267</pub-id><pub-id pub-id-type="pmid">24362694</pub-id></element-citation></ref><ref id="B59-vaccines-11-00491"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Atwell</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>McFarland</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Muresan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perlowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Libous</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yogev</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Live-attenuated vaccines prevent respiratory syncytial virus&#8211;associated illness in young children</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2021</year><volume>203</volume><fpage>594</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1164/rccm.202005-1660OC</pub-id><pub-id pub-id-type="pmid">32871092</pub-id><pub-id pub-id-type="pmcid">PMC7924568</pub-id></element-citation></ref><ref id="B60-vaccines-11-00491"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostad</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Stobart</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.C.G.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>M.L.</given-names></name></person-group><article-title>Enhancing the thermostability and immunogenicity of a respiratory syncytial virus (RSV) live-attenuated vaccine by incorporating unique RSV line19F protein residues</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01568-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.01568-17</pub-id><pub-id pub-id-type="pmid">29263264</pub-id><pub-id pub-id-type="pmcid">PMC5827408</pub-id></element-citation></ref><ref id="B61-vaccines-11-00491"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stauft</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Kalkeri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Koidei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kushnir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tasker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>J.R.</given-names></name></person-group><article-title>A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>2943</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.056</pub-id><pub-id pub-id-type="pmid">32107060</pub-id><pub-id pub-id-type="pmcid">PMC7092643</pub-id></element-citation></ref><ref id="B62-vaccines-11-00491"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luongo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>U.J.</given-names></name></person-group><article-title>Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>1985</fpage><lpage>1996</lpage><pub-id pub-id-type="doi">10.1128/JVI.02769-12</pub-id><pub-id pub-id-type="pmid">23236065</pub-id><pub-id pub-id-type="pmcid">PMC3571493</pub-id></element-citation></ref><ref id="B63-vaccines-11-00491"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ueno</surname><given-names>T.</given-names></name></person-group><article-title>The versatile manipulations of self-assembled proteins in vaccine design</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>1934</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22041934</pub-id><pub-id pub-id-type="pmid">33669238</pub-id><pub-id pub-id-type="pmcid">PMC7919822</pub-id></element-citation></ref><ref id="B64-vaccines-11-00491"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Tompkins</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name></person-group><article-title>A novel influenza virus hemagglutinin-respiratory syncytial virus (RSV) fusion protein subunit vaccine against influenza and RSV</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>10792</fpage><lpage>10804</lpage><pub-id pub-id-type="doi">10.1128/JVI.01724-13</pub-id><pub-id pub-id-type="pmid">23903841</pub-id><pub-id pub-id-type="pmcid">PMC3807402</pub-id></element-citation></ref><ref id="B65-vaccines-11-00491"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.F.</given-names></name><name name-style="western"><surname>Bont</surname><given-names>L.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fauroux</surname><given-names>B.</given-names></name><name name-style="western"><surname>Paes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Figueras-Aloy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Checchia</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Carbonell-Estrany</surname><given-names>X.</given-names></name></person-group><article-title>Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children</article-title><source>Infect. Dis. Ther.</source><year>2018</year><volume>7</volume><fpage>87</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s40121-018-0188-z</pub-id><pub-id pub-id-type="pmid">29470837</pub-id><pub-id pub-id-type="pmcid">PMC5840107</pub-id></element-citation></ref><ref id="B66-vaccines-11-00491"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saravolatz</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Empey</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Peebles</surname><given-names>R.S.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Kolls</surname><given-names>J.K.</given-names></name></person-group><article-title>Pharmacologic advances in the treatment and prevention of respiratory syncytial virus</article-title><source>Clin. Infect. Dis.</source><year>2010</year><volume>50</volume><fpage>1258</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">20235830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/651603</pub-id><pub-id pub-id-type="pmcid">PMC2851489</pub-id></element-citation></ref><ref id="B67-vaccines-11-00491"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaberolansar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name></person-group><article-title>Recent advances in the development of subunit-based RSV vaccines</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>53</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1105134</pub-id><pub-id pub-id-type="pmid">26506139</pub-id></element-citation></ref><ref id="B68-vaccines-11-00491"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isaacs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>S.T.M.</given-names></name><name name-style="western"><surname>Wijesundara</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>C.L.D.</given-names></name><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Ranasinghe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>K.J.</given-names></name></person-group><article-title>Adjuvant selection for influenza and RSV prefusion subunit vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>71</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020071</pub-id><pub-id pub-id-type="pmid">33498370</pub-id><pub-id pub-id-type="pmcid">PMC7909420</pub-id></element-citation></ref><ref id="B69-vaccines-11-00491"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tahir</surname><given-names>U.l.</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shokat</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Muneer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ashfaq</surname><given-names>U.A.</given-names></name><name name-style="western"><surname>Javed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zahid</surname><given-names>B.</given-names></name><name name-style="western"><surname>Saari</surname><given-names>N.</given-names></name></person-group><article-title>Multiepitope-based subunit vaccine design and evaluation against respiratory syncytial virus using reverse vaccinology approach</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>288</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020288</pub-id><pub-id pub-id-type="pmid">32521680</pub-id><pub-id pub-id-type="pmcid">PMC7350008</pub-id></element-citation></ref><ref id="B70-vaccines-11-00491"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#8212;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B71-vaccines-11-00491"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knezevic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Peden</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.-N.</given-names></name></person-group><article-title>Development of mRNA vaccines: Scientific and regulatory issues</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9020081</pub-id><pub-id pub-id-type="pmid">33498787</pub-id><pub-id pub-id-type="pmcid">PMC7910833</pub-id></element-citation></ref><ref id="B72-vaccines-11-00491"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espeseth</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Cejas</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Citron</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>DiStefano</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Donnell</surname><given-names>G.O.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Swoyer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Touch</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection</article-title><source>NPJ Vaccines</source><year>2020</year><volume>5</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41541-020-0163-z</pub-id><pub-id pub-id-type="pmid">32128257</pub-id><pub-id pub-id-type="pmcid">PMC7021756</pub-id></element-citation></ref><ref id="B73-vaccines-11-00491"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashiwagi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ikematsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Uemori</surname><given-names>M.</given-names></name><name name-style="western"><surname>Awamura</surname><given-names>S.</given-names></name><collab>Laninamivir Prophylaxis Study Group</collab></person-group><article-title>Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza</article-title><source>Rev Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw255</pub-id><pub-id pub-id-type="pmid">27118785</pub-id><pub-id pub-id-type="pmcid">PMC4946013</pub-id></element-citation></ref><ref id="B74-vaccines-11-00491"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hynicka</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>C.R.</given-names></name></person-group><article-title>Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients</article-title><source>Ann. Pharmacother.</source><year>2012</year><volume>46</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1345/aph.1Q553</pub-id><pub-id pub-id-type="pmid">22395247</pub-id></element-citation></ref><ref id="B75-vaccines-11-00491"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagga</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Veldman</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balaratnam</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lambkin-Williams</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oxford</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>McClain</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals</article-title><source>Antivir. Ther.</source><year>2013</year><volume>18</volume><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.3851/IMP2629</pub-id><pub-id pub-id-type="pmid">23714753</pub-id></element-citation></ref><ref id="B76-vaccines-11-00491"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>M.D.</given-names></name></person-group><article-title>Emerging influenza antiviral resistance threats</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>6</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq012</pub-id><pub-id pub-id-type="pmid">21148489</pub-id><pub-id pub-id-type="pmcid">PMC3086431</pub-id></element-citation></ref><ref id="B77-vaccines-11-00491"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munywoki</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Koech</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Agoti</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Kibirige</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kipkoech</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cane</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Medley</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Nokes</surname><given-names>D.J.</given-names></name></person-group><article-title>Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding</article-title><source>Epidemiol. Infect.</source><year>2015</year><volume>143</volume><fpage>804</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1017/S0950268814001393</pub-id><pub-id pub-id-type="pmid">24901443</pub-id><pub-id pub-id-type="pmcid">PMC4411640</pub-id></element-citation></ref><ref id="B78-vaccines-11-00491"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vuitika</surname><given-names>L.</given-names></name><name name-style="western"><surname>Prates-Syed</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>J.D.Q.</given-names></name><name name-style="western"><surname>Crema</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>C&#244;rtes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lima</surname><given-names>J.B.M.</given-names></name><name name-style="western"><surname>Camara</surname><given-names>N.O.S.</given-names></name><name name-style="western"><surname>Schimke</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Cabral-Marques</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Vaccines against emerging and neglected infectious diseases: An overview</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1385</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10091385</pub-id><pub-id pub-id-type="pmid">36146463</pub-id><pub-id pub-id-type="pmcid">PMC9503027</pub-id></element-citation></ref><ref id="B79-vaccines-11-00491"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hutvagner</surname><given-names>G.</given-names></name></person-group><article-title>RNA-based therapeutics: From antisense oligonucleotides to miRNAs</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>137</elocation-id><pub-id pub-id-type="doi">10.3390/cells9010137</pub-id><pub-id pub-id-type="pmid">31936122</pub-id><pub-id pub-id-type="pmcid">PMC7016530</pub-id></element-citation></ref><ref id="B80-vaccines-11-00491"><label>80.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bathula</surname><given-names>N.V.</given-names></name><name name-style="western"><surname>Popova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blakney</surname><given-names>A.</given-names></name></person-group><article-title>Delivery vehicles for self-amplifying RNA</article-title><source>Messenger RNA Therapeutics</source><publisher-name>Springer</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2022</year><fpage>355</fpage><lpage>370</lpage></element-citation></ref><ref id="B81-vaccines-11-00491"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papukashvili</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rcheulishvili</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.G.</given-names></name></person-group><article-title>Self-Amplifying RNA Approach for Protein Replacement Therapy</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>12884</elocation-id><pub-id pub-id-type="doi">10.3390/ijms232112884</pub-id><pub-id pub-id-type="pmid">36361673</pub-id><pub-id pub-id-type="pmcid">PMC9655356</pub-id></element-citation></ref><ref id="B82-vaccines-11-00491"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Pareek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>L.</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>R.</given-names></name><name name-style="western"><surname>DeVincenzo</surname><given-names>J.</given-names></name></person-group><article-title>The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin</article-title><source>Influenza Other. Respir. Viruses</source><year>2017</year><volume>11</volume><fpage>525</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1111/irv.12503</pub-id><pub-id pub-id-type="pmid">28990339</pub-id><pub-id pub-id-type="pmcid">PMC5705693</pub-id></element-citation></ref><ref id="B83-vaccines-11-00491"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ju</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>P.</given-names></name></person-group><article-title>Inhibitors of influenza virus polymerase acidic (PA) endonuclease: Contemporary developments and perspectives</article-title><source>J. Med. Chem.</source><year>2017</year><volume>60</volume><fpage>3533</fpage><lpage>3551</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b01227</pub-id><pub-id pub-id-type="pmid">28118010</pub-id></element-citation></ref><ref id="B84-vaccines-11-00491"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>R.</given-names></name><name name-style="western"><surname>Plemper</surname><given-names>R.K.</given-names></name></person-group><article-title>Structure-guided design of small-molecule therapeutics against RSV disease</article-title><source>Expert Opin. Drug. Discov.</source><year>2016</year><volume>11</volume><fpage>543</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1517/17460441.2016.1174212</pub-id><pub-id pub-id-type="pmid">27046051</pub-id><pub-id pub-id-type="pmcid">PMC5074927</pub-id></element-citation></ref><ref id="B85-vaccines-11-00491"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Chemaly</surname><given-names>R.F.</given-names></name></person-group><article-title>Management of RSV infections in adult recipients of hematopoietic stem cell transplantation</article-title><source>Blood J. Am. Soc. Hematol.</source><year>2011</year><volume>117</volume><fpage>2755</fpage><lpage>2763</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-08-263400</pub-id><pub-id pub-id-type="pmid">21139081</pub-id></element-citation></ref><ref id="B86-vaccines-11-00491"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaijyan</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Govindasamy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development</article-title><source>Cell Rep. Methods</source><year>2022</year><volume>2</volume><fpage>100287</fpage><pub-id pub-id-type="doi">10.1016/j.crmeth.2022.100287</pub-id><pub-id pub-id-type="pmid">36160049</pub-id><pub-id pub-id-type="pmcid">PMC9499982</pub-id></element-citation></ref><ref id="B87-vaccines-11-00491"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonavia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pusateri Keaney</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kuhen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Seepersaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Radetich</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dewhurst</surname><given-names>J.</given-names></name><name name-style="western"><surname>Balabanis</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV)</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>6739</fpage><lpage>6744</lpage><pub-id pub-id-type="doi">10.1073/pnas.1017142108</pub-id><pub-id pub-id-type="pmid">21502533</pub-id><pub-id pub-id-type="pmcid">PMC3084118</pub-id></element-citation></ref><ref id="B88-vaccines-11-00491"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwon</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Na</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Douaisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kane</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Nanostructured glycan architecture is important in the inhibition of influenza A virus infection</article-title><source>Nat. Nanotechnol.</source><year>2017</year><volume>12</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nnano.2016.181</pub-id><pub-id pub-id-type="pmid">27775724</pub-id></element-citation></ref><ref id="B89-vaccines-11-00491"><label>89.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lal</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Uthaman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name></person-group><article-title>Silver Nanoparticle as an Effective Antiviral Agent</article-title><source>Polymer Nanocomposites Based on Silver Nanoparticles</source><publisher-name>Springer</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2021</year><fpage>247</fpage><lpage>265</lpage></element-citation></ref><ref id="B90-vaccines-11-00491"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Numata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grinkova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Sligar</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Voelker</surname><given-names>D.R.</given-names></name></person-group><article-title>Nanodiscs as a therapeutic delivery agent: Inhibition of respiratory syncytial virus infection in the lung</article-title><source>Int. J. Nanomed.</source><year>2013</year><volume>8</volume><fpage>1417</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S39888</pub-id><pub-id pub-id-type="pmcid">PMC3663477</pub-id><pub-id pub-id-type="pmid">23717040</pub-id></element-citation></ref><ref id="B91-vaccines-11-00491"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ansar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Speshock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ivanciuc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Casola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garofalo</surname><given-names>R.</given-names></name></person-group><article-title>Antiviral and immunomodulatory activity of silver nanoparticles in experimental RSV infection</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>732</elocation-id><pub-id pub-id-type="doi">10.3390/v11080732</pub-id><pub-id pub-id-type="pmid">31398832</pub-id><pub-id pub-id-type="pmcid">PMC6723559</pub-id></element-citation></ref><ref id="B92-vaccines-11-00491"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Power</surname><given-names>U.F.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.M.</given-names></name><name name-style="western"><surname>Kauvar</surname><given-names>L.M.</given-names></name></person-group><article-title>Respiratory syncytial virus: Targeting the G protein provides a new approach for an old problem</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01302-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.01302-17</pub-id><pub-id pub-id-type="pmid">29118126</pub-id><pub-id pub-id-type="pmcid">PMC5774885</pub-id></element-citation></ref><ref id="B93-vaccines-11-00491"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>An</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>4491</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-22826-4</pub-id><pub-id pub-id-type="pmid">29540836</pub-id><pub-id pub-id-type="pmcid">PMC5852162</pub-id></element-citation></ref><ref id="B94-vaccines-11-00491"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shambaugh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heeke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frantz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Paliard</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>S.L.</given-names></name></person-group><article-title>Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4472</fpage><lpage>4478</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.025</pub-id><pub-id pub-id-type="pmid">26206269</pub-id></element-citation></ref><ref id="B95-vaccines-11-00491"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reeves</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hardelid</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Warburton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pebody</surname><given-names>R.G.</given-names></name></person-group><article-title>Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007&#8211;2012</article-title><source>Influenza Other. Respir. Viruses</source><year>2017</year><volume>11</volume><fpage>122</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1111/irv.12443</pub-id><pub-id pub-id-type="pmid">28058797</pub-id><pub-id pub-id-type="pmcid">PMC5304572</pub-id></element-citation></ref><ref id="B96-vaccines-11-00491"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bloom-Feshbach</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Charu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tamerius</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simonsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Viboud</surname><given-names>C.</given-names></name></person-group><article-title>Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): A global comparative review</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e54445</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0054445</pub-id><pub-id pub-id-type="pmid">23457451</pub-id><pub-id pub-id-type="pmcid">PMC3573019</pub-id></element-citation></ref><ref id="B97-vaccines-11-00491"><label>97.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.-H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.-S.</given-names></name></person-group><article-title>28 Chitosan and Chitosan Derivatives as DNA and siRNA Carriers</article-title><source>Chitin, Chitosan, Oligosaccharides and Their Derivatives</source><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2010</year><fpage>377</fpage></element-citation></ref><ref id="B98-vaccines-11-00491"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radu</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>Caidi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>L.M.</given-names></name></person-group><article-title>Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>9632</fpage><lpage>9636</lpage><pub-id pub-id-type="doi">10.1128/JVI.00451-10</pub-id><pub-id pub-id-type="pmid">20592094</pub-id><pub-id pub-id-type="pmcid">PMC2937657</pub-id></element-citation></ref><ref id="B99-vaccines-11-00491"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>H.</given-names></name></person-group><article-title>Discovery of piperazinylquinoline derivatives as novel respiratory syncytial virus fusion inhibitors</article-title><source>ACS Med. Chem. Lett.</source><year>2016</year><volume>7</volume><fpage>558</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.5b00234</pub-id><pub-id pub-id-type="pmid">27326326</pub-id><pub-id pub-id-type="pmcid">PMC4904258</pub-id></element-citation></ref><ref id="B100-vaccines-11-00491"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krarup</surname><given-names>A.</given-names></name><name name-style="western"><surname>Truan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Furmanova-Hollenstein</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bouchier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bisschop</surname><given-names>I.J.M.</given-names></name><name name-style="western"><surname>Widjojoatmodjo</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name><etal/></person-group><article-title>A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8143</fpage><pub-id pub-id-type="doi">10.1038/ncomms9143</pub-id><pub-id pub-id-type="pmcid">PMC4569726</pub-id><pub-id pub-id-type="pmid">26333350</pub-id></element-citation></ref><ref id="B101-vaccines-11-00491"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hause</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Henke</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Avadhanula</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Tapia</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.A.</given-names></name></person-group><article-title>Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0175792</elocation-id><pub-id pub-id-type="pmid">28414749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0175792</pub-id><pub-id pub-id-type="pmcid">PMC5393888</pub-id></element-citation></ref><ref id="B102-vaccines-11-00491"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deval</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dyatkina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Prhavc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Serebryany</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Discovery of 4&#8242;-chloromethyl-2&#8242;-deoxy-3&#8242;, 5&#8242;-di-O-isobutyryl-2&#8242;-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treating human respiratory syncytial virus infection</article-title><source>J. Med. Chem.</source><year>2015</year><volume>58</volume><fpage>1862</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1021/jm5017279</pub-id><pub-id pub-id-type="pmid">25667954</pub-id></element-citation></ref><ref id="B103-vaccines-11-00491"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name></person-group><article-title>Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant</article-title><source>Hum. Vaccin. Immunother.</source><year>2015</year><volume>11</volume><fpage>397</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.4161/21645515.2014.995056</pub-id><pub-id pub-id-type="pmid">25607884</pub-id><pub-id pub-id-type="pmcid">PMC4514371</pub-id></element-citation></ref><ref id="B104-vaccines-11-00491"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevaert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groaz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Naesens</surname><given-names>L.</given-names></name></person-group><article-title>Nucleoside analogs for managing respiratory virus infections: Mechanism of action and clinical efficacy</article-title><source>Curr. Opin. Virol.</source><year>2022</year><volume>57</volume><fpage>101279</fpage><pub-id pub-id-type="doi">10.1016/j.coviro.2022.101279</pub-id><pub-id pub-id-type="pmid">36403338</pub-id><pub-id pub-id-type="pmcid">PMC9671222</pub-id></element-citation></ref><ref id="B105-vaccines-11-00491"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pruijssers</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M.R.</given-names></name></person-group><article-title>Nucleoside analogs for treating coronavirus infections</article-title><source>Curr. Opin. Virol.</source><year>2019</year><volume>35</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.04.002</pub-id><pub-id pub-id-type="pmid">31125806</pub-id><pub-id pub-id-type="pmcid">PMC7102703</pub-id></element-citation></ref><ref id="B106-vaccines-11-00491"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>J.K.W.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>M.Y.T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>S.W.S.</given-names></name></person-group><article-title>siRNA versus miRNA as therapeutics for gene silencing</article-title><source>Mol. Ther. Nucleic Acids</source><year>2015</year><volume>4</volume><fpage>e252</fpage><pub-id pub-id-type="doi">10.1038/mtna.2015.23</pub-id><pub-id pub-id-type="pmid">26372022</pub-id><pub-id pub-id-type="pmcid">PMC4877448</pub-id></element-citation></ref><ref id="B107-vaccines-11-00491"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#216;lholm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Cullberg</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Richelsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>S.B.</given-names></name></person-group><article-title>Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants</article-title><source>Int. J. Obes.</source><year>2010</year><volume>34</volume><fpage>1546</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1038/ijo.2010.98</pub-id><pub-id pub-id-type="pmid">20531350</pub-id></element-citation></ref><ref id="B108-vaccines-11-00491"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dinwiddie</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Harrod</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.C.</given-names></name></person-group><article-title>Anti-inflammatory effect of MUC1 during respiratory syncytial virus infection of lung epithelial cells in vitro</article-title><source>Am. J. Physiol. -Lung Cell. Mol. Physiol.</source><year>2010</year><volume>298</volume><fpage>L558</fpage><lpage>L563</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00225.2009</pub-id><pub-id pub-id-type="pmid">20081068</pub-id><pub-id pub-id-type="pmcid">PMC2853342</pub-id></element-citation></ref><ref id="B109-vaccines-11-00491"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antoine</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Trigilio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Adelung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>D.</given-names></name></person-group><article-title>Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection</article-title><source>Antiviral. Res.</source><year>2012</year><volume>96</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.020</pub-id><pub-id pub-id-type="pmid">23047013</pub-id><pub-id pub-id-type="pmcid">PMC3535478</pub-id></element-citation></ref><ref id="B110-vaccines-11-00491"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baraldi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Checcucci Lisi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heinrichs</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ricc&#242;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vassilouthis</surname><given-names>N.</given-names></name></person-group><article-title>RSV disease in infants and young children: Can we see a brighter future?</article-title><source>Hum. Vaccines Immunother.</source><year>2022</year><volume>18</volume><fpage>2079322</fpage><pub-id pub-id-type="doi">10.1080/21645515.2022.2079322</pub-id><pub-id pub-id-type="pmcid">PMC9721445</pub-id><pub-id pub-id-type="pmid">35724340</pub-id></element-citation></ref><ref id="B111-vaccines-11-00491"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bansal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>B.</given-names></name></person-group><article-title>Human papillomavirus-associated cancers: A growing global problem</article-title><source>Int. J. Appl. Basic Med. Res.</source><year>2016</year><volume>6</volume><fpage>84</fpage><pub-id pub-id-type="pmid">27127735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/2229-516X.179027</pub-id><pub-id pub-id-type="pmcid">PMC4830161</pub-id></element-citation></ref><ref id="B112-vaccines-11-00491"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruckwardt</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name></person-group><article-title>Immunological lessons from respiratory syncytial virus vaccine development</article-title><source>, Immunity</source><year>2019</year><volume>51</volume><fpage>429</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.08.007</pub-id><pub-id pub-id-type="pmid">31533056</pub-id></element-citation></ref><ref id="B113-vaccines-11-00491"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zohar</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Das</surname><given-names>J.</given-names></name><name name-style="western"><surname>Devadhasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karpinski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Citron</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>DiStefano</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Touch</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><fpage>41</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2021.11.006</pub-id><pub-id pub-id-type="pmid">34879230</pub-id></element-citation></ref><ref id="B114-vaccines-11-00491"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmoele-Thoma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Maddur</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Danaf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eze</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fok-Seang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kabir</surname><given-names>G.</given-names></name><name name-style="western"><surname>Catchpole</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Vaccine efficacy in adults in a respiratory syncytial virus challenge study</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>2377</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2116154</pub-id><pub-id pub-id-type="pmid">35731653</pub-id></element-citation></ref><ref id="B115-vaccines-11-00491"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Center</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Tita</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Radley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Houghton</surname><given-names>J.</given-names></name><name name-style="western"><surname>McGrory</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Gomme</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Prefusion F protein&#8211;based respiratory syncytial virus immunization in pregnancy</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>1615</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2106062</pub-id><pub-id pub-id-type="pmid">35476650</pub-id></element-citation></ref><ref id="B116-vaccines-11-00491"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacheco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Monreal</surname><given-names>I.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Imbiakha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sahler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jager</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>B.</given-names></name><etal/></person-group><article-title>New Class of Broad-Spectrum Antivirals Improves Influenza Virus Vaccine Development</article-title><source>Res. Sq.</source><year>2022</year></element-citation></ref><ref id="B117-vaccines-11-00491"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergeron</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name></person-group><article-title>Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)</article-title><source>Expert Opin. Investig. Drugs</source><year>2022</year><volume>31</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1080/13543784.2022.2020248</pub-id><pub-id pub-id-type="pmid">34937485</pub-id></element-citation></ref><ref id="B118-vaccines-11-00491"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Long-Term Infection and Pathogenesis in a Novel Mouse Model of Human Respiratory Syncytial Virus</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>1740</elocation-id><pub-id pub-id-type="doi">10.3390/v14081740</pub-id><pub-id pub-id-type="pmid">36016362</pub-id><pub-id pub-id-type="pmcid">PMC9415064</pub-id></element-citation></ref><ref id="B119-vaccines-11-00491"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binns</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tuckerman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Licciardi</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Wurzel</surname><given-names>D.</given-names></name></person-group><article-title>Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions</article-title><source>J. Paediatr. Child Health</source><year>2022</year><volume>58</volume><fpage>1741</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1111/jpc.16197</pub-id><pub-id pub-id-type="pmid">36073299</pub-id><pub-id pub-id-type="pmcid">PMC9826513</pub-id></element-citation></ref><ref id="B120-vaccines-11-00491"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozzola</surname><given-names>E.</given-names></name></person-group><article-title>Respiratory syncytial virus resurgence in Italy: The need to protect all neonates and young infants</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>380</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph19010380</pub-id><pub-id pub-id-type="pmcid">PMC8744776</pub-id><pub-id pub-id-type="pmid">35010637</pub-id></element-citation></ref><ref id="B121-vaccines-11-00491"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>I.</given-names></name><name name-style="western"><surname>AlFouzan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moraes</surname><given-names>T.J.</given-names></name></person-group><article-title>Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>154</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12020154</pub-id><pub-id pub-id-type="pmid">36839426</pub-id><pub-id pub-id-type="pmcid">PMC9961958</pub-id></element-citation></ref><ref id="B122-vaccines-11-00491"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elawar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gotte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fearns</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>D.J.</given-names></name></person-group><article-title>Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics</article-title><source>New Drug Dev. Known Emerg. Viruses</source><year>2022</year><volume>80</volume></element-citation></ref><ref id="B123-vaccines-11-00491"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murray</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Reener</surname><given-names>Z.B.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Sancilio</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Tripp</surname><given-names>R.A.</given-names></name></person-group><article-title>Probenecid inhibits respiratory syncytial virus (RSV) replication</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>912</elocation-id><pub-id pub-id-type="doi">10.3390/v14050912</pub-id><pub-id pub-id-type="pmid">35632652</pub-id><pub-id pub-id-type="pmcid">PMC9147281</pub-id></element-citation></ref><ref id="B124-vaccines-11-00491"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sake</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kosch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blockus</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gunesch</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Friesland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trummer</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Grethe</surname><given-names>C.</given-names></name><name name-style="western"><surname>K&#252;hnel</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages</article-title><source>Antimicrob. Agents Chemother.</source><year>2022</year><volume>66</volume><fpage>e01032-22</fpage><pub-id pub-id-type="doi">10.1128/aac.01032-22</pub-id><pub-id pub-id-type="pmid">36346232</pub-id><pub-id pub-id-type="pmcid">PMC9765014</pub-id></element-citation></ref><ref id="B125-vaccines-11-00491"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Thwaites</surname><given-names>R.S.</given-names></name></person-group><article-title>Mucosal Immune Responses to Respiratory Syncytial Virus</article-title><source>Cells</source><year>2022</year><volume>11</volume><elocation-id>1153</elocation-id><pub-id pub-id-type="doi">10.3390/cells11071153</pub-id><pub-id pub-id-type="pmid">35406717</pub-id><pub-id pub-id-type="pmcid">PMC8997753</pub-id></element-citation></ref><ref id="B126-vaccines-11-00491"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wollny</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pitt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Metcalfe</surname><given-names>A.</given-names></name></person-group><article-title>Predicting prolonged length of stay in hospitalized children with respiratory syncytial virus</article-title><source>Pediatr. Res.</source><year>2022</year><volume>92</volume><fpage>1780</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1038/s41390-022-02008-9</pub-id><pub-id pub-id-type="pmid">35301421</pub-id></element-citation></ref><ref id="B127-vaccines-11-00491"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shekhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sheikh</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S.</given-names></name></person-group><article-title>Impact of COVID-19 on the changing patterns of respiratory syncytial virus infections</article-title><source>Infect. Dis. Rep.</source><year>2022</year><volume>14</volume><fpage>558</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.3390/idr14040059</pub-id><pub-id pub-id-type="pmid">35893478</pub-id><pub-id pub-id-type="pmcid">PMC9394296</pub-id></element-citation></ref><ref id="B128-vaccines-11-00491"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#245;es</surname><given-names>E.A.</given-names></name></person-group><article-title>Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>226</volume><fpage>S1</fpage><lpage>S9</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac252</pub-id><pub-id pub-id-type="pmid">35822854</pub-id></element-citation></ref><ref id="B129-vaccines-11-00491"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nu&#241;ez Castrejon</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kauvar</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>DuBois</surname><given-names>R.M.</given-names></name></person-group><article-title>Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens</article-title><source>J. Virol.</source><year>2022</year><volume>96</volume><fpage>e0220121</fpage><pub-id pub-id-type="doi">10.1128/jvi.02201-21</pub-id><pub-id pub-id-type="pmid">35266806</pub-id><pub-id pub-id-type="pmcid">PMC9006937</pub-id></element-citation></ref><ref id="B130-vaccines-11-00491"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phijffer</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Bont</surname><given-names>L.J.</given-names></name></person-group><article-title>Are We Ready for Maternal Respiratory Syncytial Virus Vaccination?</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>2053</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab613</pub-id><pub-id pub-id-type="pmid">34932123</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>